Login to Your Account



The Pharma Summit 2012

Can Biopharma Go from 'Value Destruction' to Double Returns?

By Nuala Moran
Staff Writer

Wednesday, February 15, 2012
LONDON – Pricing pressures, piled on top of R&D productivity problems, have cut the return on investment and left many asking if developing new drugs is worth the risk.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription